Chinese Biopharmaceutical Firm Junshi Biosciences Targets $414M IPO In Hong Kong

Chinese biopharmaceutical company Shanghai Junshi Biosciences Co. has filed for a US$414 million initial public offering in Hong Kong, according to a security filing released today.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in